Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.60 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.60 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.60 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KDM6B | O15054 | 1/20 | 0.47 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31522172 | 1.00 | NR4A1 (0.60) | NR4A1NR4A2NR4A3TNFSTING1 | |
| SCHEMBL30771576 | 0.98 | NR4A1 (0.58) | NR4A1NR4A2NR4A3TNFSTING1 | |
| Hydrochloric Acid SCHEMBL29816682 | 0.98 | NR4A1 (0.58) | NR4A1NR4A2NR4A3TNFSTING1 | |
| SCHEMBL28135495 | 0.88 | MAPK8 (0.49) | NR4A1NR4A2NR4A3TNFSTING1 | |
| SCHEMBL117921 | 0.85 | NR4A1 (0.60) | NR4A1NR4A2NR4A3CDC25BCSNK2A2 | |
| SCHEMBL29702097 | 0.85 | NR4A1 (0.60) | NR4A1NR4A2NR4A3CDC25BCSNK2A2 | |
| SCHEMBL30937994 | 0.84 | HASPIN (0.47) | NR4A1NR4A2NR4A3TNFSTING1 | |
| SCHEMBL29715203 | 0.84 | KDM4E (0.59) | TNFKDM4EALDH1A1KMT2ATDP1 | |
| SCHEMBL28892310 | 0.84 | TNF (0.46) | NR4A1NR4A2NR4A3TNFSTING1 | |
| SCHEMBL14893839 | 0.84 | HASPIN (0.47) | NR4A1NR4A2NR4A3TNFSTING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108059206-A | For three area's adsorptive reactors of orthophosphates in Adsorption waste water | 北京益清源环保科技有限公司 | 2018-05-22 | — | — | CN | claimed |
| CN-107778230-A | A kind of synthetic method of tetrahydro isoquinoline derivative | 湖南华腾制药有限公司 | 2018-03-09 | — | — | CN | claimed |
| CN-104447547-B | Synthesis method of 4-aminoisoquinoline-8-methyl formate | 苏州康润医药有限公司 | 2017-04-19 | — | — | CN | claimed |
| WO-2025054318-A1 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-115232144-B | Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-111447931-B | Anticancer/antifibrotic compounds | 加利福尼亚大学董事会 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023180189-A1 | MPRO TARGETING ANTIVIRAL COMPOUNDS | EXSCIENTIA AI LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| CN-111377934-B | Heterocyclic compound, preparation and application thereof | 中国科学院上海药物研究所 | 2023-01-24 | — | — | CN | disclosed |
| WO-2023277630-A1 | GALACTOSIDE DERIVATIVE AS GALECTIN-3 INHIBITOR | 주식회사 티움바이오 | 2023-01-05 | — | — | WO | disclosed |
| CN-115232144-A | Nitrogen-containing fused ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-111447931-A | Anti-cancer/anti-fibrosis compounds | 加利福尼亚大学董事会 | 2020-07-24 | — | — | CN | disclosed |
| US-7202257-B2 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC (US) | 2007-04-10 | — | — | US | disclosed |
| US-20070037808-A1 | p38 kinase inhibitors | DECIPHERA PHARMACEUTICALS, LLC | 2007-02-15 | — | — | US | disclosed |
| WO-2006014290-A2 | ANTI-INFLAMMATORY MEDICAMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050288286-A1 | Anti-inflammatory medicaments | DECIPHERA PHARMACEUTICALS, LLC | 2005-12-29 | — | — | US | disclosed |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | MERCK SHARP & DOHME LTD. (GB) | 2005-05-19 | — | — | US | disclosed |
| EP-1490340-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LTD. (GB) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080578-A1 | HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN | MERCK SHARP & DOHME LIMITED (GB) | 2003-10-02 | — | — | WO | disclosed |
| US-4062961-A | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINES | SMITHKLINE CORPORATION (US) | 1977-12-13 | — | — | US | disclosed |
| US-3988339-A | 7 OR 8-SUBSTITUTED 1,2,3,4-TETRAHYDRO-ISOQUINOLINE | SMITHKLINE CORPORATION (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037808-A1 | p38 kinase inhibitors | MAPK1, MAP3K8, MAP3K1 | NR4A1 3239/4885NR4A2 2370/4885NR4A3 2448/4885 |
| US-20050288286-A1 | Anti-inflammatory medicaments | MIF, PTGES2, TNF | NR4A1 3816/4885NR4A2 2369/4885NR4A3 2314/4885 |
| US-20050107388-A1 | Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain | ARRB1, OPRL1, CNR1 | NR4A1 24/4885NR4A2 66/4885NR4A3 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.